105 research outputs found
Interplay of Kondo effect and strong spin-orbit coupling in multi-hole ultraclean carbon nanotubes
We report on cotunneling spectroscopy magnetoconductance measurements of
multi-hole ultraclean carbon nanotube quantum dots in the SU(4) Kondo regime
with strong spin-orbit coupling. Successive shells show a gradual weakening of
the Kondo effect with respect to the spin-orbital splittings, leading to an
evolution from SU(4) to SU(2) symmetry with a suppressed conductance at half
shell filling. The extracted energy level spectrum, overally consistent with
negligible disorder in the nanotube, shows in the half filled case large
renormalizations due to Coulombian effects.Comment: 5 pages, 4 figures, 1 supplementary fil
Multifragmentation of a very heavy nuclear system (II): bulk properties and spinodal decomposition
The properties of fragments and light charged particles emitted in
multifragmentation of single sources formed in central 36AMeV Gd+U collisions
are reviewed. Most of the products are isotropically distributed in the
reaction c.m. Fragment kinetic energies reveal the onset of radial collective
energy. A bulk effect is experimentally evidenced from the similarity of the
charge distribution with that from the lighter 32AMeV Xe+Sn system. Spinodal
decomposition of finite nuclear matter exhibits the same property in simulated
central collisions for the two systems, and appears therefore as a possible
mechanism at the origin of multifragmentation in this incident energy domain.Comment: 28 pages including 14 figures; submitted to Nucl. Phys.
Study of intermediate velocity products in the Ar+Ni collisions between 52 and 95 A.MeV
Intermediate velocity products in Ar+Ni collisions from 52 to 95 A.MeV are
studied in an experiment performed at the GANIL facility with the 4
multidetector INDRA. It is shown that these emissions cannot be explained by
statistical decays of the quasi-projectile and the quasi-target in complete
equilibrium. Three methods are used to isolate and characterize intermediate
velocity products. The total mass of these products increases with the violence
of the collision and reaches a large fraction of the system mass in mid-central
collisions. This mass is found independent of the incident energy, but strongly
dependent on the geometry of the collision. Finally it is shown that the
kinematical characteristics of intermediate velocity products are weakly
dependent on the experimental impact parameter, but strongly dependent on the
incident energy. The observed trends are consistent with a
participant-spectator like scenario or with neck emissions and/or break-up.Comment: 37 pages, 13 figure
Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study)
Purpose: (1) To improve survival rates in patients with Ewing's sarcoma (ES) or peripheral neuroectodermal tumours (PNET) using semi-continuous chemotherapy and aiming to peform surgery in all; (2) To identify early prognostic factors to tailor therapy for future studies. Patients and methods One hundred and forty-one patients were entered onto the trial between January 1988 and December 1991. Induction therapy consisted of five courses of Cytoxan, 150 mg/m2 × 7 days, followed by Doxorubicin, 35 mg/m2 i.v on day 8 given at short intervals. Surgery was recommended whenever possible. The delivery of radiation therapy was based on the quality of resection and the histological response to CT. Maintenance chemotherapy consisted of vincristine + actinomycin and cytoxan + doxorubicin. The total duration of therapy was 10 months. Results After a median follow-up of 8.5 years, the projected overall survival at 5 years was 66% and disease-free survival (DFS) was 58%. In patients treated by surgery, only the histological response to CT had an influence on survival: 75% DFS for patients with a good histological response (less than 5% of cells), 48% for intermediate responders and only 20% for poor responders (≥ 30% of cells), P < 0.0001. The initial tumor volume by itself had no influence on DFS in these patients. In contrast, the tumour volume had a strong impact on DFS in patients treated by radiation therapy alone. Age had no impact on outcome. Conclusion Therapeutic trials for localized Ewing's sarcoma should be based on the histological response to chemotherapy or on the tumour volume according to the modality used for local therapy. © 2001 Cancer Research Campaign http://www.bjcancer.co
Colonic Biopsies to Assess the Neuropathology of Parkinson's Disease and Its Relationship with Symptoms
The presence of Lewy bodies and Lewy neurites (LN) has been demonstrated in the enteric nervous system (ENS) of Parkinson's disease (PD) patients. The aims of the present research were to use routine colonoscopy biopsies (1) to analyze, in depth, enteric pathology throughout the colonic submucosal plexus (SMP), and (2) to correlate the pathological burden with neurological and gastrointestinal (GI) symptoms.A total of 10 control and 29 PD patients divided into 3 groups according to disease duration were included. PD and GI symptoms were assessed using the Unified Parkinson's Disease Rating Scale part III and the Rome III questionnaire, respectively. Four biopsies were taken from the ascending and descending colon during the course of a total colonoscopy. Immunohistochemical analysis was performed using antibodies against phosphorylated alpha-synuclein, neurofilaments NF 220 kDa (NF) and tyrosine hydroxylase (TH). The density of LN, labeled by anti-phosphorylated alpha-synuclein antibodies, was evaluated using a quantitative rating score. Lewy pathology was apparent in the colonic biopsies from 21 patients and in none of the controls. A decreased number of NF-immunoreactive neurons per ganglion was observed in the SMP of PD patients compared to controls. The amount of LN in the ENS was inversely correlated with neuronal count and positively correlated with levodopa-unresponsive features and constipation.Analysis of the ENS by routine colonoscopy biopsies is a useful tool for pre-mortem neuropathological diagnosis of PD, and also provides insight into the progression of motor and non-motor symptoms
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
BACKGROUND: Acute graft-versus-host disease (GVHD) remains a major limitation of allogeneic stem-cell transplantation; not all patients have a response to standard glucocorticoid treatment. In a phase 2 trial, ruxolitinib, a selective Janus kinase (JAK1 and JAK2) inhibitor, showed potential efficacy in patients with glucocorticoid-refractory acute GVHD. METHODS: We conducted a multicenter, randomized, open-label, phase 3 trial comparing the efficacy and safety of oral ruxolitinib (10 mg twice daily) with the investigator's choice of therapy from a list of nine commonly used options (control) in patients 12 years of age or older who had glucocorticoid-refractory acute GVHD after allogeneic stem-cell transplantation. The primary end point was overall response (complete response or partial response) at day 28. The key secondary end point was durable overall response at day 56. RESULTS: A total of 309 patients underwent randomization; 154 patients were assigned to the ruxolitinib group and 155 to the control group. Overall response at day 28 was higher in the ruxolitinib group than in the control group (62% [96 patients] vs. 39% [61]; odds ratio, 2.64; 95% confidence interval [CI], 1.65 to 4.22; P<0.001). Durable overall response at day 56 was higher in the ruxolitinib group than in the control group (40% [61 patients] vs. 22% [34]; odds ratio, 2.38; 95% CI, 1.43 to 3.94; P<0.001). The estimated cumulative incidence of loss of response at 6 months was 10% in the ruxolitinib group and 39% in the control group. The median failure-free survival was considerably longer with ruxolitinib than with control (5.0 months vs. 1.0 month; hazard ratio for relapse or progression of hematologic disease, non-relapse-related death, or addition of new systemic therapy for acute GVHD, 0.46; 95% CI, 0.35 to 0.60). The median overall survival was 11.1 months in the ruxolitinib group and 6.5 months in the control group (hazard ratio for death, 0.83; 95% CI, 0.60 to 1.15). The most common adverse events up to day 28 were thrombocytopenia (in 50 of 152 patients [33%] in the ruxolitinib group and 27 of 150 [18%] in the control group), anemia (in 46 [30%] and 42 [28%], respectively), and cytomegalovirus infection (in 39 [26%] and 31 [21%]). CONCLUSIONS: Ruxolitinib therapy led to significant improvements in efficacy outcomes, with a higher incidence of thrombocytopenia, the most frequent toxic effect, than that observed with control therapy
Hemoglobins of the Corsico-Sardinian Mouflon (Ovis musimon) and their implications for the origin of Hb A in domestic sheep (Ovis aries)
International audienc
Positionneur Souple Hautes Précision Et Cadence (Prototype : Positionneur HPC 1 & 2)
Journées EEA des 28-29 mars 2006no abstrac
- …